Stock SCOL SCANDION ONCOLOGY A/S
Add to a list
To use this feature you must be a member
Log inSign up

Press Releases Scandion Oncology A/S

Equities

SCOL

DK0061031895

Delayed Nasdaq Stockholm
Other stock markets
 11:10:29 2024-05-15 EDT 		5-day change 1st Jan Change
1.35 SEK -3.57% Intraday chart for Scandion Oncology A/S +3.05% -66.21%
05-15 Transcript : Scandion Oncology A/S - Special Call
03-21 Scandion Oncology Reports Updated Phase II Corist Data, Including Topline Overall Survival CI

Press Releases

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Scandion confirms positive final Phase Ib data from PANTAX trial with SCO-101
AQ
Scandion Oncology Announces Results of Annual General Meeting and Constitution of the Board of Directors
AQ
Scandion Oncology to Host R&D Update May 15
AQ
Scandion Oncology – Notice convening the Annual General Meeting
AQ
Scandion Oncology reports promising updated Phase II CORIST data, including topline overall survival
AQ
Scandion Oncology - Annual Report 2023
AQ
Scandion Oncology reports second confirmed partial response in the Phase IIa CORIST Part 3 trial
AQ
Scandion Oncology Q4 2023 - Striving towards randomised controlled data
AQ
Scandion Oncology – Q4 & yearend report 2023
AQ
Invitation to Scandion Oncology webcast and conference call February 28, 2024
AQ
Scandion Oncology reports positive topline Phase IIa data from the CORIST Part 3 trial
AQ
Scandion Oncology receives Notice of Allowance for patent to enhance US patent exclusivity on SCO-101
AQ
CORIST part 3 topline data are expected in the second half of January 2024
AQ
Scandion Oncology identifies potentially effective treatment of gastric cancer
AQ
Scandion Oncology is granted new Composition of Matter-patent on lead compound SCO-101 extending its exclusivity until at least 2042
AQ
Scandion Oncology Q3 2023 - Intriguing CORIST part 2 data
AQ
Scandion Oncology – Interim Report Q3 2023
AQ
Final data from the Phase IIa open-label CORIST part 2 trial shows impressive median Overall Survival of 10.4 months
AQ
Invitation to Scandion Oncology webcast and conference call November 22, 2023
AQ
Phase Ib PANTAX trial is successfully completed and establishes the maximal tolerated dose with positive safety profile and pharmacokinetic data.
AQ
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. SCOL Stock
  4. News Scandion Oncology A/S
  5. Press Releases
-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.
BENEFIT NOW